ArticleMicrobial cell factories2025
A bioprocess optimization study to enhance the production of Menaquinone-7 using Bacillus subtilis MM26.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Enhanced production of Nattokinase by Bacillus aryabhattai RP6 isolated from fermented Brassica oleracea.BMC biotechnology · 2026Article
- Directed screening and spatial coupling of farnesyl diphosphate synthase for enhancing menaquinone-7 production in Bacillus subtilis.Microbial cell factories · 2026Article
- Metabolic engineering of Escherichia coli BW25113 for the production of Vitamin KJournal of biological engineering · 2026Article
- Statistical optimization of fermentation conditions for enhanced production of Nattokinase from Bacillus subtilis MM26.BMC biotechnology · 2026Article
- Extraction, LC-QTOF-MS profiling of bacterial menaquinone (MK) and characterization of CuFeScientific reports · 2025Article
- Metabolic Engineering Strategy forFoods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMenaquinone-7 (MK-7) has a vital significance in promoting human health and tackling several global health concerns which makes its production extremely important. MK-7 is not easily accessible at a reasonable cost due to the poor fermentation yields and the existence of several laborious downstream unit processes. Efficient manufacturing methods are essential to meet the global requirements due to the increasing demand in the pharmaceutical and nutraceutical industries. This research study focuses on the enhanced production of MK-7 from Bacillus subtilis MM26 isolated from fermented home-made wine.
resultsA suitable MK-7 production medium for Bacillus subtilis MM26 was determined and the yield was found to be 67 ± 0.6 mg/L. The one factor at a time (OFAT) results showed that medium containing lactose, glycine, with a pH 7, a temperature of 37 °C, and an inoculum size of 2.5% (2 × 10⁶ CFU/mL) was optimal synthesis of MK-7. RSM indicated that incubation time, carbon and nitrogen sources were the factors significantly affecting the MK-7 yield. RSM predicted optimal conditions, which yielded a maximum concentration of 442 ± 2.08 mg/L of MK-7.
conclusionsThe outcomes of this study demonstrated the potential of Bacillus subtilis MM26 in large-scale industrial production of MK-7. The yield of MK-7 was amplified efficiently by integration of OFAT and RSM, paving the way for cost-efficient industrial production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.